Santhera Pharmaceuticals Holding AG

SWX:SANN Stock Report

Market Cap: CHF 109.6m

Santhera Pharmaceuticals Holding Valuation

Is SANN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SANN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SANN (CHF9.05) is trading below our estimate of fair value (CHF584.19)

Significantly Below Fair Value: SANN is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SANN?

Other financial metrics that can be useful for relative valuation.

SANN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA2.1x
PEG Ratio0.05x

Price to Earnings Ratio vs Peers

How does SANN's PE Ratio compare to its peers?

The above table shows the PE ratio for SANN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.5x
IDIA Idorsia
8.9x-14.0%CHF 255.1m
FENC Fennec Pharmaceuticals
46.2x57.4%US$123.7m
OBSN ObsEva
0.02xn/aCHF 140.6k
2142 HBM Holdings
6.7xn/aHK$1.1b
SANN Santhera Pharmaceuticals Holding
1.7x35.4%CHF 109.6m

Price-To-Earnings vs Peers: SANN is good value based on its Price-To-Earnings Ratio (1.7x) compared to the peer average (15.5x).


Price to Earnings Ratio vs Industry

How does SANN's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.8%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a34.8%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: SANN is good value based on its Price-To-Earnings Ratio (1.7x) compared to the European Biotechs industry average (25.1x).


Price to Earnings Ratio vs Fair Ratio

What is SANN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SANN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio1.7x
Fair PE Ratio21.2x

Price-To-Earnings vs Fair Ratio: SANN is good value based on its Price-To-Earnings Ratio (1.7x) compared to the estimated Fair Price-To-Earnings Ratio (21.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SANN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 9.05
CHF 32.00
+253.6%
21.9%CHF 39.00CHF 25.00n/a2
Sep ’25CHF 9.00
CHF 34.50
+283.3%
13.0%CHF 39.00CHF 30.00n/a2
Aug ’25CHF 9.29
CHF 34.50
+271.4%
13.0%CHF 39.00CHF 30.00n/a2
Jul ’25CHF 8.51
CHF 34.50
+305.4%
13.0%CHF 39.00CHF 30.00n/a2
Jan ’25CHF 9.81
CHF 71.00
+623.8%
57.7%CHF 112.00CHF 30.00n/a2
Dec ’24CHF 9.59
CHF 70.00
+629.9%
60.0%CHF 112.00CHF 28.00n/a2
Nov ’24CHF 10.82
CHF 70.00
+547.0%
60.0%CHF 112.00CHF 28.00n/a2
Oct ’24CHF 8.34
CHF 68.00
+715.3%
64.7%CHF 112.00CHF 24.00CHF 9.172
Sep ’24CHF 8.64
CHF 68.00
+687.0%
64.7%CHF 112.00CHF 24.00CHF 9.002
Aug ’24CHF 8.59
CHF 68.00
+691.6%
64.7%CHF 112.00CHF 24.00CHF 9.292
Feb ’24CHF 8.79
CHF 88.00
+901.1%
54.5%CHF 136.00CHF 40.00CHF 9.352
Jan ’24CHF 13.80
CHF 88.00
+537.7%
54.5%CHF 136.00CHF 40.00CHF 9.812

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies